Immunohistological analysis of HPV L1 capsid protein and p16 protein in low-grade dysplastic lesions of the uterine cervix

Pathology Research and Practice

Volumn 206, Issue 12, 2010, Pages 816-820

  Hoshikawa, Satomi ^a,b   Sano, Takaaki ^a   Yoshida, Tomomi ^a   Ito, Hideaki ^b   Oyama, Tetsunari ^a   Fukuda, Toshio ^a  

^a GUNMA UNIVERSITY   (Japan)

^b MAEBASHI RED CROSS HOSPITAL   (Japan)

Author keywords

Human papillomavirus; L1 capsid protein; P16; Progression cases; Regression cases

Indexed keywords

CAPSID PROTEIN L1; PROTEIN P16;

ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER RISK; CONTROLLED STUDY; DISEASE SEVERITY; DYSPLASIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN FUNCTION; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ADULT; AGED; CAPSID PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 78649738322     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.09.005     Document Type: Article

References (19)

1. Parkin D.M., Bray F., Ferlay J., et al. Estimating the World Cancer Burden, Globocan 2000. Int. J. Cancer. 2001, 94:153-156.
2. Mcmurray H.M., Nguyen D., Westbrook T.F., et al. Biology of human papillomaviruses. Int. J. Exp. Path. 2001, 82:15-33.
3. Doobar J. The papillomavirus life cycle. J. Clin. Virol. 2005, 32:S7-S15.
4. Roden R., Wu T.C. How will HPV vaccines affect cervical cancer?. Nat. Rev. 2006, 6:753-763.
5. Lowly D.R., Schiller J.T. Prophylactic human papillomavirus vaccines. J. Clin. Invest. 2006, 116:1167-1173.
6. Cantor S.B., Atkinson E.N., Cardenas-Turanzas M., et al. Natural history of cervical intraepithelial neoplasia; a meta analysis. Acta Cytol. 2005, 49:405-415.
7. Yoshida T., Fukuda T., Sano T., et al. Usefulness of liquid based cytology specimens for immunocytochemical study of p16 expression and human papillomavirus testing; comparative study using simultaneously sampled histology materials. Cancer Cytopathol. 2004, 102:100-108.
8. Nakao Y., Yang X., Yokoyama M., et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Brit. J. Cancer. 1997, 75:1417-1420.
9. Khleif S.N., Gregori J., Yee C.L., et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:4350-4354.
10. Hawley-Nelson P., Vousden K.H., Hubbert N.I., et al. HPV16E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989, 8:3905-3910.
11. Munger K., Phelps W.C., Bubb V., et al. The E6 and E7 genes of human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 1989, 63:4417-4421.
12. Yoshikawa H., Kawana T., Kitagawa K., et al. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn. J. Cancer Res. 1991, 82:524-531.
13. Nagri G., Bellisano G., Zannori G.F., et al. P16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of cervix uteri. Am. J. Surg. Pathol. 2008, 32:1715-1720.
14. Yoshida T., Sano T., Kanuma T., et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid based cytology samples from uterine cervical lesions. Cancer cytopathol. 2008, 114:83-88.
15. Huang M.Z., Li H.B., Nie X.M., et al. An analysis on the combination expression of HPV L1 capsid protein and p16INK4a in cervical lesions. Diagn. Cytopathol. Diagn. Cytopathol. 2010, 38:573-578.
16. Yu L., Wang L., Zhong J., Chen S. Diagnostic value of p16 INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens. Cancer Cytopathol. 2010, 118:47-55.
17. Melsheimer P., Kaul S., Dobeck S., et al. Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol. 2003, 47:124-128.
18. Griesser H., Sabder H., Hillfrich R., et al. Correlation of immunochemical detection of HPV L1 caosid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia. Anal. Quant. Cytol. Histol. 2004, 26:241-245.
19. Hillfrich R., Hariri J. Prognostic relevance of human papillomavirus L1 capsid protein detection with mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal. Quant. Cytol. Histol. 2008, 30:78-82.